These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 21372205)
1. DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism. Yang X; Popescu NC; Zimonjic DB Cancer Res; 2011 Apr; 71(8):2916-25. PubMed ID: 21372205 [TBL] [Abstract][Full Text] [Related]
2. CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth. Kim TY; Jackson S; Xiong Y; Whitsett TG; Lobello JR; Weiss GJ; Tran NL; Bang YJ; Der CJ Proc Natl Acad Sci U S A; 2013 Oct; 110(42):16868-73. PubMed ID: 24082123 [TBL] [Abstract][Full Text] [Related]
3. DLC1 SAM domain-binding peptides inhibit cancer cell growth and migration by inactivating RhoA. Joshi R; Qin L; Cao X; Zhong S; Voss C; Min W; Li SSC J Biol Chem; 2020 Jan; 295(2):645-656. PubMed ID: 31806702 [TBL] [Abstract][Full Text] [Related]
4. The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylserine, PLCD1, and Caveolin-1. Sanchez-Solana B; Wang D; Qian X; Velayoudame P; Simanshu DK; Acharya JK; Lowy DR Mol Cancer; 2021 Nov; 20(1):141. PubMed ID: 34727930 [TBL] [Abstract][Full Text] [Related]
5. Morphological changes and nuclear translocation of DLC1 tumor suppressor protein precede apoptosis in human non-small cell lung carcinoma cells. Yuan BZ; Jefferson AM; Millecchia L; Popescu NC; Reynolds SH Exp Cell Res; 2007 Nov; 313(18):3868-80. PubMed ID: 17888903 [TBL] [Abstract][Full Text] [Related]
6. Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells. Du X; Qian X; Papageorge A; Schetter AJ; Vass WC; Liu X; Braverman R; Robles AI; Lowy DR Cancer Res; 2012 Sep; 72(17):4405-16. PubMed ID: 22693251 [TBL] [Abstract][Full Text] [Related]
7. Regulation of deleted in liver cancer 1 tumor suppressor by protein-protein interactions and phosphorylation. Ko FC; Ping Yam JW Int J Cancer; 2014 Jul; 135(2):264-9. PubMed ID: 24114040 [TBL] [Abstract][Full Text] [Related]
8. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Wong CM; Yam JW; Ching YP; Yau TO; Leung TH; Jin DY; Ng IO Cancer Res; 2005 Oct; 65(19):8861-8. PubMed ID: 16204057 [TBL] [Abstract][Full Text] [Related]
9. Tensin1 positively regulates RhoA activity through its interaction with DLC1. Shih YP; Sun P; Wang A; Lo SH Biochim Biophys Acta; 2015 Dec; 1853(12):3258-65. PubMed ID: 26427649 [TBL] [Abstract][Full Text] [Related]
10. The Annexin A2/S100A10 Complex: The Mutualistic Symbiosis of Two Distinct Proteins. Bharadwaj A; Kempster E; Waisman DM Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944495 [TBL] [Abstract][Full Text] [Related]
11. The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation. Scholz RP; Gustafsson JO; Hoffmann P; Jaiswal M; Ahmadian MR; Eisler SA; Erlmann P; Schmid S; Hausser A; Olayioye MA Exp Cell Res; 2011 Feb; 317(4):496-503. PubMed ID: 21087603 [TBL] [Abstract][Full Text] [Related]
12. Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function. Chan LK; Ko FC; Ng IO; Yam JW PLoS One; 2009; 4(5):e5572. PubMed ID: 19440389 [TBL] [Abstract][Full Text] [Related]
13. Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1. Tripathi BK; Grant T; Qian X; Zhou M; Mertins P; Wang D; Papageorge AG; Tarasov SG; Hunter KW; Carr SA; Lowy DR J Cell Biol; 2017 Dec; 216(12):4255-4270. PubMed ID: 29114068 [TBL] [Abstract][Full Text] [Related]
14. Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin. MacLeod TJ; Kwon M; Filipenko NR; Waisman DM J Biol Chem; 2003 Jul; 278(28):25577-84. PubMed ID: 12730231 [TBL] [Abstract][Full Text] [Related]
15. S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors. Kwon M; MacLeod TJ; Zhang Y; Waisman DM Front Biosci; 2005 Jan; 10():300-25. PubMed ID: 15574370 [TBL] [Abstract][Full Text] [Related]
16. Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding partner S100A10/p11. He KL; Deora AB; Xiong H; Ling Q; Weksler BB; Niesvizky R; Hajjar KA J Biol Chem; 2008 Jul; 283(28):19192-200. PubMed ID: 18434302 [TBL] [Abstract][Full Text] [Related]
17. SRC and ERK cooperatively phosphorylate DLC1 and attenuate its Rho-GAP and tumor suppressor functions. Tripathi BK; Anderman MF; Qian X; Zhou M; Wang D; Papageorge AG; Lowy DR J Cell Biol; 2019 Sep; 218(9):3060-3076. PubMed ID: 31308216 [TBL] [Abstract][Full Text] [Related]
19. Multiple functions of S100A10, an important cancer promoter. Saiki Y; Horii A Pathol Int; 2019 Nov; 69(11):629-636. PubMed ID: 31612598 [TBL] [Abstract][Full Text] [Related]
20. Cell surface protease activation during RAS transformation: Critical role of the plasminogen receptor, S100A10. Madureira PA; Bharadwaj AG; Bydoun M; Garant K; O'Connell P; Lee P; Waisman DM Oncotarget; 2016 Jul; 7(30):47720-47737. PubMed ID: 27351226 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]